InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by DUGGAN ROBERT W, Chief Executive Officer. Officer active across 3 companies, notably Summit Therapeutics Inc.. Cumulatively, 8 filings have been logged. Total volume traded: €205m. The latest transaction was disclosed on 11 May 2026 — Acquisition. Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
€11m660,233 shares@ €16.71480.65% mcap20.7% of flow
Common Stock
SEC:0001437749-26-017478·
Ideal exit: 5 Feb 2027 (T+270)
€11m660,233 shares@ €16.71480.65% mcap10.4% of flow
Common Stock
SEC:0001437749-26-017478:0·
Ideal exit: 5 Feb 2027 (T+270)
5,683,163 shares
Common Stock
SEC:0001387131-22-006924:0·
21,135 shares
Common Stock
SEC:0001104659-22-064838:0·
€42m3,048,780 shares@ €13.83182.48% mcap79.3% of flow
Common Stock
SEC:0001209191-21-045022·
Ideal exit: 27 Mar 2022 (T+270)
€42m3,048,780 shares@ €13.83182.48% mcap39.6% of flow
Common Stock
SEC:0001209191-21-045022:0·
Ideal exit: 27 Mar 2022 (T+270)
€49m11,365,921 shares@ €4.3383100.0% of flow
Common Stock
SEC:0000921895-21-001335·
Ideal exit: 6 Feb 2022 (T+270)
€49m11,365,921 shares@ €4.33830.38% mcap50.0% of flow
Common Stock
SEC:0000921895-21-001335:0·
Ideal exit: 6 Feb 2022 (T+270)
8 of 8 declarations
About DUGGAN ROBERT W
Robert W. Duggan is the Chief Executive Officer and Director of Summit Therapeutics Inc. and PULSE Biosciences, Inc. He is responsible for the strategic direction of these companies, which focus on developing innovative treatments in the healthcare field. His leadership is essential for the growth and innovation of these firms.
